APPLICATION
ANDA203078
TYPE
ANDA
ORIGINAL APPROVAL
2022-06-28
LATEST ACTION
2024-10-09
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
CISATRACURIUM BESYLATEPrescription
CISATRACURIUM BESYLATE EQ 10MG BASE/ML · INJECTABLE · INJECTION
CISATRACURIUM BESYLATEPrescription
CISATRACURIUM BESYLATE EQ 2MG BASE/ML · INJECTABLE · INJECTION
Approval history
2024-10-09Labeling · Supplement 3 · standardAP
2023-04-06Labeling · Supplement 1 · standardAP
2022-06-28UNKNOWN · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.